Background: The hepatitis C virus (HCV) is currently present worldwide and is the principal cause of chronic hepatitis C and hepatocellular carcinoma, thus representing one of the most important public health concern. The most advanced knowledge of the replicative cycle of this virus has permitted the identification of certain biological targets for which drugs with a direct antiviral action have been developed (DAA).

Patients and Methods: In the present study, we present the results obtained in the first 24 months of use of these new drugs in our Clinic. Data regarding the first 360 treatments delivered between January 2015 and December 2016 were analyzed. A quantitative dosage of HCV-RNA was evaluated 12 weeks after the end of therapy.

Results: A sustained virological response at week 12 (SVR12) was noted in 346 cases (96.1%), 13 of which (3.6%) demonstrated a relapse within 12 weeks at the end of therapy (relapsers), and in one case (0.3%) there was no response (non-responder).

Conclusions: The triple therapy was shown to be highly potent even in the most difficult patients, with a negative viremia within 4 weeks from initiation. Follow-up studies of patients with advanced cirrhosis (Child A and B) are necessary to evaluate the long-term efficacy of the therapy and the impact on the difficult complications of the advanced liver disease. A more extensive use of resistance testing before initiating treatment might be considered, especially in patients with an extensive pre-DAA therapy history.